论文部分内容阅读
目的探讨左卡尼汀联合阿托伐他汀对维持性血液透析(MHD)患者微炎症状态的影响。方法 40例行维持性血液透析患者为研究对象,对其进行6个月的观察,研究前3个月未使用左卡尼汀及阿托伐他汀治疗,研究后3个月患者每次血液透析后给予左卡尼汀联合予阿托伐他汀治疗。比较治疗前后患者的总胆固醇(TG)、C反应蛋白(CRP)、白细胞介素6(IL-6)和肿瘤坏死因子-α(TNF-α)水平。结果治疗后,40例患者监测肝功均正常,无一例肌痛及肌无力发生,无一例退出试验的现象发生。治疗后患者的TG、CRP、IL-6、TNF-α水平分别为(5.01±0.59)mmol/L、(7.86±1.82)mg/L、(65.13±6.23)ng/L、(4.11±0.62)ng/ml,均低于治疗前的(6.68±1.58)mmol/L、(10.98±2.57)mg/L、(82.68±9.11)ng/L、(5.78±1.07)ng/ml,差异均具有统计学意义(P<0.05)。结论左卡尼汀联合阿托伐他汀能够改善维持性血液透析患者的微炎症状态,值得在临床推广。
Objective To investigate the effect of levocarnitine and atorvastatin on the micro-inflammatory status in maintenance hemodialysis (MHD) patients. Methods Forty patients with maintenance hemodialysis were enrolled in this study. The patients were observed for 6 months. The patients were treated with L-carnitine and atorvastatin for the first 3 months. After 3-month follow-up hemodialysis After giving levocarnitine to atorvastatin treatment. The levels of total cholesterol (TG), C-reactive protein (CRP), interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α) in patients before and after treatment were compared. Results After treatment, all the 40 patients were monitored for normal liver function, none of them had myalgia and myasthenia gravis. None of the patients exited the test. The levels of TG, CRP, IL-6 and TNF-α were (5.01 ± 0.59) mmol / L, (7.86 ± 1.82) mg / L and (65.13 ± 6.23) ng / L and (4.11 ± 0.62) (6.68 ± 1.58) mmol / L, (10.98 ± 2.57) mg / L, (82.68 ± 9.11) ng / L and (5.78 ± 1.07) ng / ml respectively before treatment, the differences were statistically significant Significance (P <0.05). Conclusion L-carnitine combined with atorvastatin can improve the status of micro-inflammation in maintenance hemodialysis patients, which is worthy of clinical promotion.